# Commemorating the 175th Anniversary of Pfizer, Inc., and recognizing the company's service to the citizens of the State of New York and the World

**Bill ID:** K2359
**Session:** 2024
**Sponsor:** Tony Simone
**Status:** Adopted
**PDF:** [K2359 PDF](https://legislation.nysenate.gov/pdf/bills/2024/K2359)

---

## Full Text

Assembly Resolution No. 2359
 
BY: M. of A. Simone
 
  COMMEMORATING  the  175th  Anniversary  of Pfizer,
  Inc., and recognizing the company's service  to  the
  citizens of the State of New York and the World
 
  WHEREAS,  It  is the sense of this Legislative Body to recognize the
achievements of those  individuals  and  businesses  that  substantially
contribute  to  the  economic  vitality  of  their  communities, thereby
enhancing the economic well-being of the entire Empire State; and
 
  WHEREAS, Attendant to such concern, and  in  full  accord  with  its
long-standing  traditions,  this  Legislative  Body  is  justly proud to
commemorate the 175th Anniversary of Pfizer, Inc.; and
 
  WHEREAS, Pfizer is a research-based global  pharmaceutical  company,
headquartered  in  New  York  State,  whose  mission  is  to  advance
breakthroughs that improve patients' lives; and
 
  WHEREAS, Across New York  State,  Pfizer  employs  more  than  6,000
colleagues  and  contracted  employees,  manages  clinical  trial  and
investigator sites, and invests in strategic partnerships  and  external
research efforts with small biotech companies and universities; and
 
  WHEREAS,  Located  in  Pearl  River,  New  York,  the Pfizer Vaccine
Research  and  Development  facility  develops  first-in-class  and
best-in-class  vaccines  against  diseases  of significant importance to
public health, impacting all  ages  and  geographies,  and  Pearl  River
scientists  are  working  to develop vaccines against serious infectious
diseases as well as cancer therapeutics; and
 
  WHEREAS, Pfizer, Inc., has established the School of Science program
at its headquarters in New York  City,  designed  to  inspire  the  next
generation of scientists at an early age; and
 
  WHEREAS,  In  1849,  Pfizer, Inc., was founded by Charles Pfizer and
Charles Erhart when they opened a fine-chemicals  company  in  Brooklyn,
New York; and
 
  WHEREAS,  In  1941,  Pfizer,  Inc.,  responded to an appeal from the
United States Government to expedite the manufacture of  penicillin  for
the treatment of allied soldiers fighting in World War II; and
 
  WHEREAS,  For  the  past  175  years,  Pfizer, Inc., has been at the
forefront of innovation and the acceleration of scientific advancements;
today, there are more than 300 Pfizer medicines across the globe; and
 
  WHEREAS, Every day, the colleagues of Pfizer, Inc., work across both
developed  and  emerging  markets  to  advance  wellness,  prevention,
treatments,  and  cures  that  challenge the most feared diseases of our
time; consistent with the company's responsibility as one of the world's
premier  innovative  biopharmaceutical  companies,  the  company  is
collaborating  with  healthcare  providers,  governments,  and  local
communities to support and expand access to reliable, affordable  health
care around the world; and
 
 
  WHEREAS,  Pfizer, Inc., has an extensive history in vaccine research
and development, taking bold, new  approaches  to  translate  scientific
research  into  medicines  for  people  fighting  cancer, working toward
developing  potential  therapies  for  cardiometabolic  diseases  and
inflammatory  diseases,  helping  to ensure that patients have access to
critical anti-infective therapies, and pioneering science that  aims  to
address unmet medical needs for patients with rare diseases; and
 
  WHEREAS,  The  industry-leading  portfolio and extensive pipeline of
Pfizer, Inc., include core mechanisms of action to  attack  cancer  from
multiple  angles,  including molecules, antibody-drug conjugates (ADCs),
bispecific antibodies, and other immune-oncology biologics; and
 
  WHEREAS, Pfizer, Inc., exemplifies its purpose by sourcing the  best
science in the world, partnering with others in the healthcare system to
help  improve  access  to  its  medicines, using digital technologies to
enhance its drug discovery and development, as well as patient outcomes,
and leading the conversation to  advocate  for  innovation  and  patient
policies; and
 
  WHEREAS,  Pfizer,  Inc.,  works  with  policy  leaders,  regulatory
agencies, healthcare providers, healthcare  associations,  distributors,
insurers,  pharmacies, patient advocacy groups, and other pharmaceutical
companies to combat the risk which counterfeit  medicines  pose  to  the
health of our communities; and
 
  WHEREAS, The Pfizer Multicultural Health Equity Collective (MHEC), a
cooperative  of  Pfizer  colleagues and more than 40 non-profit partners
across  the  United  States,  including  community  groups,  healthcare
provider  associations,  legislative  caucuses,  and  patient  advocacy
groups, has created "An  Action  Guide  to  Disrupt  Inequitable  Health
Outcomes,"  which  highlights actionable solutions to disrupt drivers of
health  inequities  across  four  key  areas--Healthcare  Facilities  &
Delivery, Research and Data, Workforce Pathways, and Policy; and
 
  WHEREAS, Access to medicine is a cornerstone of commitment to health
care;  Pfizer RxPathways connects eligible patients in the United States
to a range of its assistance programs that  provide  insurance  support,
co-pay assistance, and medicines for low or no cost; and
 
  WHEREAS, Pfizer, Inc., is working to reduce the environmental impact
of  its  medicines, advance diversity, and address health disparities to
create a healthier and more equitable world; and
 
  WHEREAS, On this auspicious occasion of the 175th  Anniversary,  the
members  of  this Legislative Body extend special recognition to Pfizer,
Inc., for its record of service to the citizens of the State of New York
and the World; now, therefore, be it
 
  RESOLVED, That this Legislative Body pause in its  deliberations  to
commemorate the 175th Anniversary of Pfizer, Inc.; and be it further
 
  RESOLVED,  That  a  copy  of this Resolution, suitably engrossed, be
transmitted to Pfizer, Inc.